Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C181771> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- NCIT_C181771 IAO_0000115 "A chemoimmunotherapy regimen consisting of cyclophosphamide and doxorubicin followed by pembrolizumab, used as a neoadjuvant or adjuvant treatment for HER-2 (EGFR2; ErbB2)-negative and hormone receptor-negative breast cancer." @default.
- NCIT_C181771 NCIT_NHC0 "C181771" @default.
- NCIT_C181771 NCIT_P106 "Therapeutic or Preventive Procedure" @default.
- NCIT_C181771 NCIT_P108 "AC Followed by Pembrolizumab Regimen" @default.
- NCIT_C181771 NCIT_P208 "CL1664645" @default.
- NCIT_C181771 NCIT_R123 NCIT_C106432 @default.
- NCIT_C181771 NCIT_R123 NCIT_C124946 @default.
- NCIT_C181771 NCIT_R123 NCIT_C128037 @default.
- NCIT_C181771 NCIT_R123 NCIT_C129824 @default.
- NCIT_C181771 NCIT_R123 NCIT_C129825 @default.
- NCIT_C181771 NCIT_R123 NCIT_C141144 @default.
- NCIT_C181771 NCIT_R123 NCIT_C143250 @default.
- NCIT_C181771 NCIT_R123 NCIT_C1590 @default.
- NCIT_C181771 NCIT_R123 NCIT_C1594 @default.
- NCIT_C181771 NCIT_R123 NCIT_C163758 @default.
- NCIT_C181771 NCIT_R123 NCIT_C1748 @default.
- NCIT_C181771 NCIT_R123 NCIT_C186664 @default.
- NCIT_C181771 NCIT_R123 NCIT_C1908 @default.
- NCIT_C181771 NCIT_R123 NCIT_C1909 @default.
- NCIT_C181771 NCIT_R123 NCIT_C1968 @default.
- NCIT_C181771 NCIT_R123 NCIT_C20401 @default.
- NCIT_C181771 NCIT_R123 NCIT_C2114 @default.
- NCIT_C181771 NCIT_R123 NCIT_C2115 @default.
- NCIT_C181771 NCIT_R123 NCIT_C2161 @default.
- NCIT_C181771 NCIT_R123 NCIT_C2189 @default.
- NCIT_C181771 NCIT_R123 NCIT_C259 @default.
- NCIT_C181771 NCIT_R123 NCIT_C274 @default.
- NCIT_C181771 NCIT_R123 NCIT_C2842 @default.
- NCIT_C181771 NCIT_R123 NCIT_C307 @default.
- NCIT_C181771 NCIT_R123 NCIT_C308 @default.
- NCIT_C181771 NCIT_R123 NCIT_C405 @default.
- NCIT_C181771 NCIT_R123 NCIT_C456 @default.
- NCIT_C181771 NCIT_R123 NCIT_C471 @default.
- NCIT_C181771 NCIT_R123 NCIT_C574 @default.
- NCIT_C181771 NCIT_R123 NCIT_C67502 @default.
- NCIT_C181771 NCIT_R123 NCIT_C697 @default.
- NCIT_C181771 normalizedInformationContent "100" @default.
- NCIT_C181771 referenceCount "1" @default.
- NCIT_C181771 hasExactSynonym "AC Followed by Pembrolizumab Regimen" @default.
- NCIT_C181771 hasExactSynonym "AC Plus Pembrolizumab Regimen" @default.
- NCIT_C181771 hasExactSynonym "AC-Pembrolizumab Regimen" @default.
- NCIT_C181771 hasExactSynonym "AC/Pembrolizumab Regimen" @default.
- NCIT_C181771 hasExactSynonym "Adriamycin/Cytoxan Followed by Keytruda Regimen" @default.
- NCIT_C181771 hasExactSynonym "Cyclophosphamide-Doxorubicin-Pembrolizumab Regimen" @default.
- NCIT_C181771 hasExactSynonym "Cyclophosphamide-Doxorubicin-Pembrolizumab" @default.
- NCIT_C181771 hasExactSynonym "Cyclophosphamide/Doxorubicin/Pembrolizumab Regimen" @default.
- NCIT_C181771 hasExactSynonym "Cyclophosphamide/Doxorubicin/Pembrolizumab" @default.
- NCIT_C181771 hasExactSynonym "Doxorubicin/Cyclophosphamide Followed by Pembrolizumab Regimen" @default.
- NCIT_C181771 inSubset NCIT_C160950 @default.
- NCIT_C181771 inSubset NCIT_C160952 @default.
- NCIT_C181771 type Class @default.
- NCIT_C181771 isDefinedBy ncit.owl @default.
- NCIT_C181771 label "AC Followed by Pembrolizumab Regimen" @default.
- NCIT_C181771 subClassOf B092dd9f618f96f573afc414e101b06e7 @default.
- NCIT_C181771 subClassOf B251c9de94ab7351c0752ef6315306ea1 @default.
- NCIT_C181771 subClassOf B96cf9372b134a6c90c97b891b731a556 @default.
- NCIT_C181771 subClassOf B9db6ceec40ae1a1df4db832b05d8abcd @default.
- NCIT_C181771 subClassOf Bd8a7e7dc838ba7e1237fae957ee0691d @default.
- NCIT_C181771 subClassOf Bedf065e1b03c06857435cd7660c9a2c6 @default.
- NCIT_C181771 subClassOf NCIT_C12218 @default.
- NCIT_C181771 subClassOf NCIT_C181771 @default.
- NCIT_C181771 subClassOf NCIT_C62634 @default.
- NCIT_C181771 subClassOf NCIT_C63358 @default.